BioMed Research International

BioMed Research International / 2012 / Article
Special Issue

Toward Personalized Cell Therapies by Using Stem Cells

View this Special Issue

Research Article | Open Access

Volume 2012 |Article ID 575471 | 15 pages |

Amniotic Mesenchymal Stem Cells: A New Source for Hepatocyte-Like Cells and Induction of CFTR Expression by Coculture with Cystic Fibrosis Airway Epithelial Cells

Academic Editor: Ken-ichi Isobe
Received15 Jun 2011
Revised13 Oct 2011
Accepted14 Oct 2011
Published22 Jan 2012


Cystic fibrosis (CF) is a monogenic disease caused by mutations in the CF transmembrane conductance regulator (CFTR) gene, with lung and liver manifestations. Because of pitfalls of gene therapy, novel approaches for reconstitution of the airway epithelium and CFTR expression should be explored. In the present study, human amniotic mesenchymal stem cells (hAMSCs) were isolated from term placentas and characterized for expression of phenotypic and pluripotency markers, and for differentiation potential towards mesoderm (osteogenic and adipogenic) lineages. Moreover, hAMSCs were induced to differentiate into hepatocyte-like cells, as demonstrated by mixed function oxidase activity and expression of albumin, alpha1-antitrypsin, and CK19. We also investigated the CFTR expression in hAMSCs upon isolation and in coculture with CF airway epithelial cells. Freshly isolated hAMSCs displayed low levels of CFTR mRNA, which even decreased with culture passages. Following staining with the vital dye CM-DiI, hAMSCs were mixed with CFBE41o- respiratory epithelial cells and seeded onto permeable filters. Flow cytometry demonstrated that 33–50% of hAMSCs acquired a detectable CFTR expression on the apical membrane, a result confirmed by confocal microscopy. Our data show that amniotic MSCs have the potential to differentiate into epithelial cells of organs relevant in CF pathogenesis and may contribute to partial correction of the CF phenotype.

1. Introduction

Human placenta may represent a fruitful reserve of stem cells for regenerative medicine. Amniotic epithelial cells (hAECs) and amniotic mesenchymal stromal cells (hAMSCs) are known to have unique characteristics, such as derivation from early embryological development, low level expression of major histocompatibility complex antigens, and a less-restricted differentiation potential [1]. In culture, hAECs and hAMSCs can differentiate toward “classic” mesodermal lineages (osteogenic, chondrogenic, and adipogenic), as well as toward cell types of all three germ layers-ectoderm, mesoderm, and endoderm (reviewed in [2, 3]). Because the amniotic membrane is discarded after delivery, it is easy to obtain without harming mothers or babies and would thereby overcome the ethical issues associated with the use of embryonic stem cells. Based on these considerations, human amniotic membrane/amnion-derived cells are considered to be a useful biological material and also a novel cell source for cell transplantation. The availability of hAECs and hAMSCs and the lack of ethical concerns for this source of stem cells are considered advantageous for their widespread use and acceptance.

Cystic fibrosis (CF) is a lethal autosomal recessive disorder due to mutations in the CF transmembrane conductance regulator (CFTR) gene, a cAMP-dependent chloride channel expressed on the apical side of epithelial cells [4]. Although CF involves many organs with secretory/absorptive properties, including the liver, the main cause of morbidity and mortality is a chronic inflammatory lung disease. Because of its monogenic nature, and since the lung is easily accessible, CF has been a target disease for gene-based therapeutic intervention; however, this approach has given unsatisfied results in terms of efficiency of gene delivery to the lung and of efficacy outcomes [5]. This partial success was due to the inefficiency of passing the mucus barrier overlying the epithelial cells and to the immune response against the gene therapy vectors [6]. Cell therapy could be a more effective treatment because allogenic normal cells and autologous engineered cells express CFTR gene. Bone marrow-derived stem cells have been the first source evaluated for homing to the lung and curative potential, but the in vivo efficiency of bone marrow stem cells to differentiate in airways epithelium is very low (0.01–0.025%) [7], as also demonstrated by different studies in CF mice [8, 9].

Recently, new cell sources for CF treatment have been characterized; MSCs from cord blood [10] and amniotic fluid stem cells [11] can differentiate in vitro and in vivo in airway epithelium. Stemming from these results on MSCs, and based on the demonstrated high plasticity of amniotic-derived stem cells, after an extensive characterization of the expression of phenotypic and pluripotency markers by hAMSCs and their differentiative potential, we preliminarily evaluated their usefulness in CF by in vitro experiments using cocultures of hAMSCs and CF-respiratory epithelial cells.

2. Materials and Methods

2.1. Isolation and Culture of Human Amniotic Mesenchymal Stromal Cells

Human amniotic mesenchymal stromal cells (hAMSCs) were isolated from term placentas (𝑛=3) which would normally be discarded after delivery. Tissues were obtained under appropriate Ethical Committee approval and signed informed consent. All infectious pathogen-positive deliveries including those involving HBV, HCV, and HIV, as well as cases of prediagnosed genetic abnormalities, were excluded. Placenta samples were procured immediately after delivery and processed under sterile conditions. After peeling from the placenta and washing with calcium- and magnesium-free HBSS (CMF-HBSS, Lonza, Treviglio, Italy) supplemented with 0.5 mM EGTA (Sigma, Milan, Italy), amnion membranes were processed to remove epithelial cells as previously reported [12]. Once epithelial cells were removed, the amniotic membranes were digested in order to collect hAMSCs [13]. Briefly, amniotic membranes were washed three times with cold HBSS, cut into pieces, and transferred into 50-mL centrifuge tubes, containing about 30–40 mL of digestion solution composed by EMEM (Lonza) supplemented with 25 mM HEPES buffer without L-glutamine (Lonza), 1 mg/mL collagenase type IV, and 25 μg/mL DNase I (both from Sigma, Milan, Italy). Membranes were incubated on a rotator between 45 min to 1.5 h, depending on tissue thickness, at 37°C. After blocking the enzymatic reaction with cold HBSS, cell suspensions were centrifuged 2 times for 5 min at 200 ×g, 4°C and counted using a Bürker chamber.

After isolation, DNA was obtained from hAMSCs and hAECs by phenol/chlorophorm extraction. Purified DNA was investigated for most frequent mutations in CFTR gene using a commercial kit (Inno-Lipa CFTR19, Inno-Lipa CFTR17+TnUpdate, Inno-Lipa CFTR-Italian Regional-Innogenetics, Ghent, Belgium).

hAMSCs were plated at a density of 1×105 cells per cm2 in standard culture medium composed by DMEM (Lonza) supplemented with 1% sodium pyruvate, 10% (v/v) heat-inactivated fetal bovine serum (FBS), 1% nonessential amino acid, 55 μM β-mercaptoethanol (all by Invitrogen, Milan, Italy), 1% L-glutamine, 1% antibiotics solution (both by Cellgro, Manassas, VA, USA), and 10 ng/mL epidermal growth factor (EGF, Sigma), according to the previously reported protocol [13]. Medium was replaced 2 h after plating in order to remove unattached contaminating epithelial cells and then every 2 days.

Every time cells reached 80% of confluence, cells were detached with trypsin-EDTA (Invitrogen), washed, counted with a Bürker chamber, and replated in a new plastic flask at a density of 1×105 cells per cm2 in order to calculate their growth curve. Doubling time was calculated inserting times and cell counts on the website

2.2. Characterization of hAMSCs
2.2.1. Flow Cytometry

Flow cytometry analyses of hAMSCs were performed immediately after dissociation and at second culture passage as previously described [14]. Briefly, cells were detached from culture flask using trypsin and, after washing, were incubated with 4% normal mouse serum/PBS/NaN3 for 20 minutes at 4°C in order to block nonspecific sites on cell membrane. Cells were then stained in the dark at 4°C for 20 minutes with 7-amino actinomycin-D (7AAD) to discriminate viable cells from fragments and dead cells and with the following monoclonal antibodies (moabs): against CD13, CD29, CD31, CD34, CD44, CD45, CD49f, CD73, CD90, CD105, CD146, CD166, EpCAM, SSEA4 (all from Becton Dickinson Biosciences, BD, Franklin Lakes, NJ, USA), and CD133-1 (Miltenyi Biotech, Bergisch Gladbach, Germany). Moabs were conjugated with fluorescein isothiocyanate (FITC) or phycoerythrin (PE) or PE-Cyanin 7 (PE-Cy7) or allophycocyanin (APC) or APC-Cyanin 7 (APC-Cy7).

For internal labelling, cells were fixed at room temperature with 4% paraformaldehyde (PFA) for 10 min and permeated with 100% ethanol for 2 min after washing with PBS. Cells were incubated with 10% FBS to block nonspecific binding, followed by primary antibodies against Oct-4 and Nanog (Santa Cruz Biotechnology, Santa Cruz, CA, USA) for 1 h; secondary PE-conjugated antibody (Invitrogen) was applied for 30 min. The fluorescence threshold between negative and positive cells was set on the basis of the reactivity of appropriate nonspecific fluorochrome-conjugated isotypic controls. At least, 106 cells were finally analysed using a FACSCanto II equipped with FACSDiva software (BD).

2.2.2. Immunofluorescence Microscopy of Cultured Cells

Plated cells were stained as reported elsewhere [14]. Fixed (4% PFA or 70% ethanol for 30 min) and permeabilized (HEPES-Triton X-100 buffer 0.25% in PBS for 20 min) cells were incubated with a blocking buffer containing 0.5 M NaCl, 20 mM NaHPO4, 0.1% Triton X-100, and 30% horse and goat serum for 30 min (all reagents were from Sigma) and then immunostained with the following primary moabs: anti-EpCAM, cytokeratin (CK)18, alpha-fetoprotein (Sigma), CK19 (Novocastra, Newcastle, UK), albumin (Dako-Cytomation, Milan, Italy), CK7, CD49f, CD29, S100A4, CD90, CD31, CD146, zonula occludens-1 (ZO-1), fibronectin, alpha1-antitrypsin, E-cadherin, and beta-catenin (BD) for 2 h. After washing, cells were incubated with the appropriate secondary FITC or Texas Red-conjugated antibodies (BD) for 1 h in the dark. Nuclei were counterstained with 4′,6-diamidino-2-phenylindole (DAPI, Sigma) for 5 min in the dark.

Images were taken using a Leica Microsystems DM IRE 2 microscope and analysed with the FW4000I software (Leica Microsystems, Milan, Italy).

2.2.3. Reverse-Transcriptase (RT)-Polymerase Chain Reaction (PCR)

CFTR mRNA expression was investigated by semiquantitative RT-PCR. Total RNA was isolated from freshly isolated and cultured cells with TRIzol® Reagent (Invitrogen), according to the manufacturer’s protocol. One μg of RNA was reverse transcribed into first strand cDNA with the High-Capacity cDNA Reverse Transcription kit (Applied Biosystems) using random primers following manufacturer’s instructions. In order to analyze the expression of CFTR gene, 100 ng of cDNA was used in a final volume of 25 μL with 200 nM dNTP, 10 pM of each outer primer (Table 1), 0.3 U Taq-DNA-polymerase, reaction buffer, and MgCl2 (Invitrogen). A second nested PCR was performed using inner primers (Table 1). Cycling conditions consisted of 95°C for 30 seconds, annealing at 60°C for 1 min and elongation at 72°C for 2 min. Cycle numbers consisted of 35 cycles. cDNA from nasal brushing from healthy control was used as positive control for CFTR analysis; no reverse-transcribed sample was used as negative control.

GeneForward primerReverse primerProduct length (bp)


In parallel, β-actin was used as house-keeping gene (Table 1). PCR products were evaluated on 1.5% agarose gel electrophoresis.

2.3. Differentiation of hAMSCs Towards Different Lineages
2.3.1. Adipogenic and Osteogenic Differentiation

To induce adipogenic and osteogenic differentiation, cells at passages 1–3 were harvested and plated on tissue culture dishes (BD) at a density of 4×103 cells per cm2. Cells were then treated with either adipogenic or osteogenic differentiation media (Lonza) for three weeks. The adipogenic protocol consisted of 4 rounds of adipogenic induction medium for 2 days followed by adipogenic maintenance medium for 3 days. The presence of adipose elements in induced cultures was determined by Oil-Red-O (Sigma) staining as follow: cells were washed in PBS, then fixed in 10% formalin for 1 h, washed in isopropanol 60%, and air dried. Cells were then incubated with Oil-Red-O staining solution for 10 min, then washed several times in PBS, and observed with an inverted microscope Eclipse TS100 (Nikon, Tokyo, Japan) equipped with a DS-FI1 CCD camera (Nikon).

In order to induce osteogenesis, cells were treated with osteogenic medium for 3 weeks with medium changes 3 times a week. The presence of calcium deposits in induced cultures was determined by Alizarin Red (Sigma) staining as follow: cells were fixed in 10% formalin for 1 h, then washed in deionized water, and incubated for 30 min at room temperature with Alizarin Red 2% in water at pH 4.2. The cells were finally washed several times to remove the excess of staining and analyzed as described above.

2.3.2. Hepatocyte Differentiation

A simple protocol [15] was used for hepatic differentiation of hAMSCs; cells were plated on type 1 collagen-coated culture dishes in DMEM supplemented with 10% FBS, 1% nonessential aminoacids, 1% L-glutamine, beta-mercaptoethanol, and 10 ng/mL of EGF for 8 days and then with IMDM with the same compounds plus 10−7 M dexamethasone (Sigma) for 6 days. One of the functions in cultured hepatocytes is that of the cytochrome P450-dependent mixed function oxidases (MFOs). Diethoxy (5,6) chloromethylfluorescein (Invitrogen) is a probe suitable for use as an in situ stain for MFO activity since this colorless molecule is metabolized in a fluorescent green compound retained in the cells [16]. Five mg of probe was eluted in 1143 μL DMSO (stock solution 10 mmol). Test medium was prepared as follow: 987 μL of RPMI, 12 μL HEPES 1 M (12 mmol final), and 1 μL probe 10 mmol (10 μmol final). Control medium was prepared as follow: 987 μL RPMI, 12 μL HEPES 1 M (12 mmol final), and 1 μL DMSO. The cells were washed in PBS and incubated with the test (or control) medium for 2 h at 37°C in a CO2 incubator. Cells were analyzed using a Leica Microsystems DM IRE 2 microscope.

After differentiation for 21 days (8 days in DMEM supplemented as above +13 days in IMDM supplemented with dexamethasone), cells were stained by means of immunofluorescence as reported above in order to verify the expression of epithelial markers.

2.4. hAMSC Labelling

Passage two hAMSCs were labeled with chloromethylbenzamido (CellTracker CM-DiI) [17]. Stock solutions of CM-DiI were prepared in dimethylsulfoxide (DMSO) at 1 ng/μL. Immediately before labelling, the stock solution was diluted up to a final concentration of 0.005 ng/μL in DMEM without phenol red. Cells grown at confluence in a T25 flask were washed with phosphate-buffered saline (PBS) and then incubated with the dye working solution for 30 min at 37°C. After labelling, cells are washed twice with PBS, then incubated at 37°C 5% CO2 for at least 24 h in the presence of fresh medium.

2.5. Cultures of Airway Epithelial Cells

16HBE14o- and CFBE41o- are human epithelial bronchial cell lines, wild type and homozygous for the F508del allele (F508del/F508del), respectively, a generous gift of Professor D. Gruenert (University of California at San Francisco, USA). Epithelial cells were grown in MEM, 10% FBS, 100 U/mL penicillin, and 100 U/mL streptomycin, alone or in Coculture with hAMSCs.

2.6. Coculture of hAMSCs with CFBE41o- Cells

Labelled hAMSCs were mixed with CFBE41o- cells at different ratios (1 : 5, 1 : 10, 1 : 15, and 1 : 20) and, in order to obtain polarized cocultures, cells were seeded on 6.5-mm diameter Snapwell, 0.4-μm pore size (Corning, Acton, MA, USA) at 1×105 per filter coated with a solution of 10 μg/mL fibronectin (BD Biosciences, CA, USA), 100 μg/mL albumin from bovine serum (Sigma-Aldrich, Milan, Italy), and 30 μg/mL bovine collagen type I (BD) dissolved in MEM. As controls, hAMSCs and CFBE41o- were seeded at 2.5×104 and 1×105 per filter, respectively. Cocultures were maintained at 37°C 5% CO2 for at least 6–8 days.

Separate cocultures were obtained by seeding hAMSCs onto the filter and CFBE41o- cells onto the bottom of the lower chamber. To obtain 1 : 5 and 1 : 10 ratios, hAMSCs were seeded at 2×104 and 1×104 and CFBE41o- cells at 8×104 and 9×104, respectively. As controls, hAMSCs were seeded at 1×105 per filter. Medium was changed daily in each chamber for 5 days, and cultures were analyzed at day 6.

2.7. CFTR Cytofluorimetric Assay

Cells were detached with trypsin-EDTA treatment and fixed in PBS containing 2% PFA for 5 min. After centrifugation at 250 ×g, the resulting pellets were washed and resuspended in PBS. The cells were then incubated with CFTR antibody MAB25031 mouse IgG2a (R&D Systems, Minneapolis, MN, USA) used at 1 : 20 dilution for 1 h at 4°C. After washing in PBS, the cells were incubated with the FITC-conjugated secondary antibody (anti-mouse used at 1 : 100; Sigma) for 1 h at 4°C, followed by two washes in PBS, and analyzed. As a background control, cocultures were incubated with secondary antibody only, and the resulting fluorescence was subtracted from the analyzed samples incubated both with primary and secondary antibodies. Data were collected using a Coulter Epix XL flow cytometer (Beckman Coulter, Fullerton, CA, USA) and analyzed with WinMDI 2.9 ( Ten thousand cells were examined in each experiment. Since physical parameters (forward scatter and side scatter) did not allow us to distinguish hAMSCs from CFBE41o- cells, specific expression of CFTR on hAMSCs was detected in the CM-DiI-labelled cells. Analyses were performed by plotting the FLH-1 channel (525 nm) against the FLH-2 channel (575 nm), identifying the CFTR-specific green signal and the red-labelled hAMSCs, respectively. The vitality was evaluated by trypan blue exclusion assay and resulted to be >98%.

2.8. Confocal Analysis of CFTR Protein

Polarized cells were washed three times with PBS and incubated in PBS, 2% BSA for 30 min on ice. Cells were incubated with CFTR antibody MAB25031 diluted 1 : 20 in PBS containing 0.2% BSA for 1 h on ice. Cells were rinsed three times with PBS and incubated with the FITC-conjugated secondary antibody diluted 1 : 100 in PBS added with 0.2% BSA for 30 min on ice. After two washes in PBS, cells were fixed in 3% PFA and 2% sucrose for 10 min. After three washes in PBS, filters were excised and placed side up on a glass slide and overlaid with a drop of Mowiol (Calbiochem, San Diego, CA, USA) followed by a coverslip. Cells were analyzed using a Nikon TE2000 microscope coupled to a Radiance 2100 confocal dual-laser scanning microscopy system (Bio-Rad, Segrate, Italy). Specimens were viewed through a 60x oil immersion objective. Digital images were processed using the program Laser Sharp 2000 (Bio-Rad).

2.9. Statistical Analysis

Statistical significance of differences was evaluated by a two-tailed unpaired Student’s 𝑡-test. Data were analyzed using Prism 4 (GraphPad Software, Inc., La Jolla, CA, USA). 𝑃 values of less than 0.05 were considered significant.

3. Results

3.1. Isolation and Characterization of hAMSCs from Human Amnion

At least 33×106 hAMSCs (range 26160×106) were recovered in each isolation (𝑛=3) with a viability of 85–90%. Inno-lipa screening revealed the absence of most frequent mutation of CFTR (86% of detection rate) in hAMSCs used in this study. After plastic adhesion, hAMSCs were characterized by a fibroblastic morphology very similar to that described for mesenchymal cells isolated from bone marrow (Figures 1(a) and 1(b)) and could be kept in culture until passages 5–10. Proliferation slowed beyond passage two. In the exponential growth phase, approximately two cell doublings were observed over 15 days, giving these cells an average doubling time of 18.03 days calculated over 28 days of culture. An example of a growth curve for hAMSCs is presented in Figure 1(c).

3.2. Flow Cytometry and Immunofluorescence Analysis

hAMSCs showed an immunophenotypic profile very similar to that of mesenchymal stem cells derived from bone marrow; that is, they are positive for CD29, CD44, CD73, CD90, and CD105 and negative for the hematopoietic markers CD34, CD133, and CD45. Freshly isolated hAMSCs showed a low expression of epithelial markers (EpCAM and CD49f), which decreased up to null expression after the first passage (Table 2).

Surface antigensFreshly isolatedPassage two
Median %RangeMedian %Range


Data were expressed as median percentage and ranges of three different experiments.

hAMSCs showed the embryonic stem cell associated surface marker SSEA4 (Figure  2(f)), while very low expression of molecular markers associated with pluripotent stem cells (Nanog and Oct-4) by flow cytometry was observed (Figures 2(d) and 2(e)).

Fluorescence microscopy confirmed the positivity for CD29 and CD90 and revealed the expression of other mesenchymal markers such as fibronectin and vimentin (Figure 3). hAMSCs were almost negative for ZO-1, a marker of tight junctions and cytokeratin (CK) 7, while stained positive for CK18.

3.3. Cell Differentiation Ability

To determine whether hAMSCs could differentiate into adipocytes, cells were allowed to grow to 70% confluence prior to induction. Morphological changes as well as formation of lipid droplets within the cells were noticeable starting from one week after induction and were visualized by Oil-Red-O staining (Figure 4(b)). Cells maintained in control medium did not show any sign of adipogenic differentiation (Figure 4(a)).

To investigate the osteogenic potential of hAMSCs, cells were cultured under appropriate condition for differentiation. The presence of calcium deposits in induced cultures was determined by Alizarin Red (Figure 4(d)). Cells maintained in control media did not show any change in their morphology and no calcium deposit (Figure 4(c)).

Hepatocyte differentiation of hAMSCs was evaluated after 14 days of induction. Cells were incubated for 2 h with diethoxy (5,6) chloromethylfluorescein. The generation of fluorescent products was evaluated by fluorescence microscopy. Although hAMSCs were of mesenchymal origin, they showed signs of hepatocyte differentiation (Figure 4(f)). Cells maintained in control medium did not show any sign of hepatocyte differentiation (Figure 4(e)).

Moreover, we performed cell immunophenotyping after hepatocyte induction (Figure 5). After hepatocyte differentiation, the number of cells expressing CK7 increased, while some cells expressed albumin and, weakly, alpha1-antitrypsin. Finally, we observed also the presence of CK19- positive cells. No alpha-fetoprotein expression was detected (not shown).

3.4. CFTR mRNA Expression

In order to see whether hAMSCs express CFTR mRNA, a semiquantitative RT-PCR assay was carried out. CFTR was detected in hAMSCs by RT-PCR only after nested PCR (Figure 6). The expression of CFTR in hAMSC appeared to decrease dramatically during culture. hAECs showed a similar expression of CFTR mRNA when studied upon isolation (Figure 6).

3.5. CFTR Protein Expression by Flow Cytometry

hAMSCs stained with CM-DiI (as described in Materials and Methods section) were mixed with CFBE41o- cells at different increasing ratios (1 : 20, 1 : 15, 1 : 10, and 1 : 5) and seeded onto semipermeable filters. In order to analyze the CFTR protein expression in hAMSC–CFBE41o- cocultures at different ratios, a flow cytometric assay was performed. This mixed population was analyzed after labelling with the CFTR antibody MAB25031 in the absence of permeabilization followed by an incubation with FITC-conjugated secondary antibody. As a positive control, CFTR labelling was assessed in normal human airway 16HBE14o- cells, resulting in 50 ± 5.0% of positive cells, as previously shown [18]. CFBE41o- cells showed less CFTR-specific labelling on the membrane (11% of positive cells), consistent with the lack of CFTR transport on the plasma membrane which is a characteristic of these cells. Plasma membrane CFTR expression was detected in only 6.2% of hAMSCs (Table 3). It was possible to detect an increase of CFTR-specific signal in CM-DiI-labeled cells at all hAMSC–CFBE41o- ratios as compared with hAMSCs cells alone. The lower the ratio of hAMSCs : CFBE41o- the lower the increase in CFTR-specific signal in CM-DiI-labeled cells, these data indicating that a critical number of hAMSCs is important in order to obtain a meaningful effect on CFTR expression. Overall, these data show that a population of hAMSCs with low CFTR expression have increased this expression upon cocultures with CF epithelial cells.

% of CM-DiI+ CFTR+ cells% of CFTR+ in whole CM-DiI+ population 𝑃

hAMSCs 6 . 2 ± 2 . 0
CFBE 1 1 . 2 ± 1 . 3 0.0006
hAMSC-CFBE 1 : 5 1 2 . 1 ± 2 . 5 5 0 . 0 ± 6 . 1 <0.0001
hAMSC-CFBE 1 : 10 7 . 5 ± 2 . 1 4 6 . 7 ± 9 . 3 <0.0001
hAMSC-CFBE 1 : 15 3 . 0 ± 0 . 4 3 3 . 2 ± 6 . 5 <0.0001
hAMSC-CFBE 1 : 20 2 . 2 ± 0 . 9 3 4 . 6 ± 8 . 7 <0.0001

Percentages of CM-DiI+ CFTR+ cells were obtained by plotting the FLH-1 channel, identifying CFTR-specific green signal, against FLH-2 channel, identifying red-labelled hAMSCs. Percentages of CFTR-expressing hAMSCs in whole CM-DiI+ population were obtained by dividing the double positive hAMSCs for all CM-DiI+ cells (with and without green signal). Data are shown as the mean ± SD of five experiments. Significance is referred to CFTR+ cells in the whole CM-DiI+ population in all conditions as compared with hMSCs alone.

To investigate the mechanism underlying the expression of CFTR in hAMSCs after cocultures with CFBE41o- cells, we performed separate cocultures of hAMSCs and CFBE41o- cells. Thus, hAMSCs were grown onto the filter whereas CFBE41o- cells were seeded onto the bottom well. After 6 days of culture, hAMSCs were analyzed for CFTR expression by cytofluorimetry. Results showed that, at the hAMSCs : CFBE41o- ratios of 1 : 5 and 1 : 10, the percentages of CFTR+ hAMSCs were 10.5±3.8 and 11.6±5.0, respectively (𝑛=3). These data, compared with those obtained in direct Coculture conditions (column “% of CFTR+ in whole CM-DiI+ population” of Table 3), indicate that a direct contact between hAMSCs and CFBE41o- is necessary to obtain a significant increase of CFTR-specific signal in hAMSCs.

3.6. CFTR Expression and Localization by Confocal Microscopy

To confirm cytofluorimetric data and to analyze CFTR expression in cell compartments, hAMSC–CFBE41o- cocultures were assayed by means of confocal microscopy. In previously published work [19], we showed that CFTR protein is expressed on the apical side of 16HBE14o-cells, while CFBE41o- cells display only intracellular staining. CFTR expression and localization was evaluated by epifluorescence with a protocol which allows to detect only surface and not intracellular CFTR (see Materials and Methods section), followed by confocal microscopy analysis. As can be seen in Figure 7, CFTR was highly expressed on the apical membrane of some hAMSCs since red labelled cells showed a green staining at membrane level (Figures 7(b)7(d)), whereas CFBE41o- monolayers in absence of hAMSCs showed essentially no specific signal for CFTR expression on the membrane (Figure 7(a)), consistent with the lack of CFTR transport to the apical membrane in CF cells. hAMSCs showed a very faint signal related to CFTR (Figure 7(e)). These data confirm cytofluorimetric analysis as to the plasma membrane expression of CFTR in labelled hMSCs which increases when Cocultured with CF cells.

4. Discussion

Human MSCs are pluripotent stem cells initially identified in postnatal bone marrow (BM) [20], which is the most common source used in clinical settings [21]. However, the use of BM has some limitations, including the low frequency of MSCs and the invasive procedure for obtaining them. Moreover, the age and disease state may affect the collection of sufficient healthy autologous BM for transplantation [2224]. Finally, expansion of autologous BM cells could represent a cumbersome and low-yield approach. In the present study, we directed our attention on a source, the amniotic membrane, which is rich in MSCs [25], is easily accessible and ethically acceptable, since the term placenta is discarded after delivery. hAMSCs have been shown to be superior in proliferation and differentiation potential to BM cells [26] and to display differentiation potential towards mesoderm lineages (osteogenic, chondrogenic, and adipogenic) similar to BM cells [2527]. Importantly, various studies have reported differentiation of hAMSCs to ectoderm (neural) [27, 28], mesoderm (skeletal muscle, cardiomyocytic, and endothelial) [26, 2931], and endoderm (pancreatic) [32] lineages.

In the present study, we isolated and characterized hAMSCs according to previously published protocols, that is, by removing the epithelial cells by enzymatic digestion and obtaining the hAMSC suspension by collagenase and DNase treatment [26, 27, 30, 33, 34]. hAMSCs show a higher proliferative potential than BM MSCs [26, 35], and, in our culture conditions, they reached a plateau after 21 days in culture, similarly to what has been seen in a previous study [26], while others have observed a plateau already at day 11 [25]. hAMSCs displayed a fibroblastic morphology and presented surface markers expressed also by BM-MSCs and cells isolated from both the amnion and other regions of the full-term placenta such as CD29, CD44, CD105, CD73, CD90, and vimentin and were negative for the hematopoietic markers CD45 and CD34 [26, 27, 3539]. They also displayed positivity for the epithelial markers CD49f and CK18; since these markers are lost upon culture, they could represent a small contamination by epithelial cells, which has been described also previously [33, 40]. This hypothesis is corroborated by CFTR mRNA expression in hAECs upon their isolation from the placenta (as shown in Figure 6). Interestingly, it has been observed that adherent cells obtained from human amniotic membranes were comprised of both round-shaped epithelial cells and spindle-shaped fibroblast-like cells prior to the first passage, whereas the epithelial cells were rarely detected after the third passage [37]. In alternative, this hybrid phenotype of hAMSCs [41] is interpreted as a sign of pluripotency and suggests that the amnion-derived cells had not completely differentiated into epithelial or mesenchymal cells [3]. Nevertheless, as shown here, the amniotic cells derived from term placenta seem to remain somewhat “plastic” and maintain the capability to differentiate and contribute to cells from different germ layers. Mesodermal differentiation of MSC from various sources was widely reported in the literature and is considered one of the principal assay to prove “stemness” of mesenchymal cells [20, 22, 29]. Not differently from previous papers, hAMSCs isolated in our experiments were able to differentiate into both adipocytes and osteocytes. In recent years, the exploitation of adipose tissue or bone marrow-derived MSC for hepatocyte differentiation and liver repair was explored by many researchers [4244] but, to the best of our knowledge, only one previous study has demonstrated that hAMSCs can differentiate into hepatocyte-like cells, although only at gene-expression level [37].

Because amniotic cells can differentiate into different cell types, we examined them with antibodies directed against well-known surface markers characteristic of embryonic stem cells. Amniotic cells express the stage-specific embryonic antigen SSEA-4 [45] although the relative proportion of SSEA-4-positive cells in initial isolates is lower than that observed with embryonic stem cells [46]. In addition to characteristic stem cell surface markers, amniotic cells show very low expression of Oct-4 and Nanog, transcription factors involved in regulating ES cells’ self-renewal and differentiation, as it has been previously shown for freshly isolated MSCs obtained from bone marrow, adipose tissue, and heart [47]. Further studies are needed to understand whether these genes are regulated during the in vitro culture conditions, so to identify regulatory pathways that mimic in vivo activation.

CF is a potential model disease for stem cell therapy because of the persistent lung inflammation that leads to damage and remodeling and can promote engraftment of stem cells [7]. A developing potential therapeutic approach for CF and other lung diseases has been stimulated by recent reports demonstrating that several cell populations derived from adult bone marrow, from amniotic fluid or from umbilical cord blood, including MSCs, endothelial progenitor cells, and circulating fibrocytes, can localize to the lung and acquire phenotypic and functional markers of mature lung-specific cells [10, 11, 48]. The results published by Wang et al. [49] and Loi et al. [8] strongly suggest that the population of BM cells relevant for repopulating the lung epithelium may be found in the plastic adherent stromal cell compartment. Besides the drawbacks presented by BM-MSCs discussed above, amniotic fluid contains a heterogeneous population of cells from fetal origin [25], whereas MSCs could not be reliably isolated from all term umbilical cordon blood samples [10, 5052].

In the present study, we propose human placenta as an ethical source of MSCs for CF therapy. The first goal was to investigate the CFTR expression in these cells. At the earliest stages of human development, CFTR protein and function have been detected in early blastocysts in the apical membrane of trophectoderm cells, while its expression at mRNA level has been shown in first trimester placenta (8-week gestation) [53]. However, no data are available concerning its mRNA and protein levels in specific cell types of term placenta. In this study, we show that a nested RT-PCR was necessary for obtaining a detectable signal from freshly isolated hAMSCs, indicating very low levels of CFTR mRNA in these cells. We have recently shown that also hematopoietic stem/progenitor cells display such low levels upon purification from the bone marrow [18]. The reason why CFTR must be kept at low expression levels in stem/progenitor cell compartments is not known at the moment. Although at this moment we do not know whether freshly isolated hAMSCs show CFTR expression or the specific band by RT-PCR is given by an epithelial contamination, CFTR mRNA was barely visible at passages one and three. Confocal microscopy confirmed these results at the protein level. Notably, CFTR was reexpressed by hAMSCs upon Coculture with epithelial cells, as demonstrated unequivocally by flow cytometry and confocal microscope analysis. At this stage, we do not know why the lower the hAMSCs : CFBE41o- ratios the lower the CFTR expression in hAMSCs. It can be speculated that this effect might be due to cross-talk between amniotic and epithelial cells, for which a critical number of hAMSCs are needed. Indeed, in other Coculture systems, developed with MSCs and chondrocytes, it has been shown universally that the more chondrocytes the lower the expression of extracellular matrix genes and functional properties of engineered cartilage [54, 55].

Also, the mechanism underlying this effect is to be discovered yet. However, indirect cocultures data give us an indication that this effect is primarily due to the contact between amnion MSCs and epithelial cells, and not to factors acting by a paracrine manner. Lung morphogenesis is an orchestrated molecular and cellular process controlled by cellular interactions with growth factors and morphogenic factors [56]. Since the cellular interactions between epithelial and mesenchymal cells in monolayer Coculture are likely to be bidirectional, a possible mode of action could be cross-talk between cells via gap junctions, which has been observed in vivo in the lung between transplanted MSCs and resident epithelial cells [57]. Recently, it has been found that MSCs could be induced to differentiate into corneal epithelium [58] or endothelium [59] in Coculture condition, but not in the indirect Coculture system where MSCs and endothelial cells were cultured in separate inserts [59]. More importantly, BM-MSCs acquired an airway epithelium phenotype when Cocultured with respiratory epithelial cells and determined a partial resumption of the chloride secretion defect in CF epithelia [49]. Although we have not analyzed the correction of the chloride transport defect in CFBE14o- monolayers by hAMSCs, based on the work by Wang et al. [49], it can be anticipated that we should see the same effect on the basic electrophysiological defect. Furthermore, since only 6–20% of corrected cells are needed to revert the basic defect in chloride secretion [60], our data showing that 33–50% of hAMSCs acquired CFTR expression shed a positive light on the use of amnion MSCs in the CF treatment.

5. Conclusions

Our data indicate hAMSCs as a novel, promising, readily accessible, and ethically compatible source of pluripotent cells that could be used in regenerative medicine. In this respect, hAMSCs present promising features as indicated by their expression of embryonic stem cell markers such as SSEA4 and by their differentiation potential towards mesodermal and endodermal lineages.

Although CF is a clinically heterogeneous disease caused by a defect in the CFTR gene affecting multiple organ systems, major morbidity and mortality are given by the lung disease; however, hepatobiliary complications of CF are increasingly common and clinically relevant as the age of patients increases [61, 62]. This study shows the differentiative potential of hAMSCs towards hepatocyte-like cells, which might be useful in CF, and highlights the need for further investigations to elucidate the mechanism mediating CFTR expression in hAMSCs upon cell to-cell interactions.

Conflict of Interests

The authors declare that they have no conflict of interests.


This study was funded by the Italian Ministry of Health (Ricerca Corrente and Law 548/93).


  1. T. Miki and S. C. Strom, “Amnion-derived pluripotent/multipotent stem cells,” Stem Cell Reviews, vol. 2, no. 2, pp. 133–142, 2006. View at: Publisher Site | Google Scholar
  2. M. Evangelista, M. Soncini, and O. Parolini, “Placenta-derived stem cells: new hope for cell therapy?” Cytotechnology, vol. 58, no. 1, pp. 33–42, 2008. View at: Publisher Site | Google Scholar
  3. O. Parolini, F. Alviano, G. P. Bagnara et al., “Concise review: isolation and characterization of cells from human term placenta: outcome of the first international workshop on placenta derived stem cells,” Stem Cells, vol. 26, no. 2, pp. 300–311, 2008. View at: Publisher Site | Google Scholar
  4. D. N. Sheppard and M. J. Welsh, “Structure and function of the CFTR chloride channel,” Physiological Reviews, vol. 79, no. 1, supplement, pp. S23–S45, 1999. View at: Google Scholar
  5. U. Griesenbach and E. W. F. W. Alton, “Cystic fibrosis gene therapy: successes, failures and hopes for the future,” Expert Review of Respiratory Medicine, vol. 3, no. 4, pp. 363–371, 2009. View at: Publisher Site | Google Scholar
  6. M. Conese, E. Copreni, D. Piro, and J. Rejman, “Gene and cell therapy for the treatment of cystic fibrosis,” Advances in Gene, Molecular and Cell Therapy, vol. 1, pp. 99–119, 2007. View at: Google Scholar
  7. D. Piro, J. Rejman, and M. Conese, “Stem cell therapy for cystic fibrosis: current status and future prospects,” Expert Review of Respiratory Medicine, vol. 2, no. 3, pp. 365–380, 2008. View at: Publisher Site | Google Scholar
  8. R. Loi, T. Beckett, K. K. Goncz, B. T. Suratt, and D. J. Weiss, “Limited restoration of cystic fibrosis lung epithelium in vivo with adult bone marrow-derived cells,” American Journal of Respiratory and Critical Care Medicine, vol. 173, no. 2, pp. 171–179, 2006. View at: Publisher Site | Google Scholar
  9. E. M. Bruscia, J. E. Price, E.-C. Cheng et al., “Assessment of cystic fibrosis transmembrane conductance regulator (CFTR) activity in CFTR-null mice after bone marrow transplantation,” Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no. 8, pp. 2965–2970, 2006. View at: Publisher Site | Google Scholar
  10. V. Sueblinvong, R. Loi, P. L. Eisenhauer et al., “Derivation of lung epithelium from human cord blood-derived mesenchymal stem cells,” American Journal of Respiratory and Critical Care Medicine, vol. 177, no. 7, pp. 701–711, 2008. View at: Publisher Site | Google Scholar
  11. G. Carraro, L. Perin, S. Sedrakyan et al., “Human amniotic fluid stem cells can integrate and differentiate into epithelial lung lineages,” Stem Cells, vol. 26, no. 11, pp. 2902–2911, 2008. View at: Publisher Site | Google Scholar
  12. T. Miki, F. Marongiu, K. Dorko et al., “Isolation of amniotic mesenchymal stem cells,” Current Protocols in Stem Cell Biology, vol. 1, supplement 12, pp. 1E.3.1–E3.10, 2010. View at: Google Scholar
  13. F. Marongiu, R. Gramignoli, Q. Sun et al., “Isolation of amniotic mesenchymal stem cells,” Current Protocols in Stem Cell Biology, vol. 1, supplement 12, pp. 1E.5.1–E.5.11, 2010. View at: Google Scholar
  14. L. Porretti, A. Cattaneo, F. Colombo et al., “Simultaneous characterization of progenitor cell compartments in adult human liver,” Cytometry A, vol. 77, no. 1, pp. 31–40, 2010. View at: Publisher Site | Google Scholar
  15. T. Miki, F. Marongiu, E. C. Ellis et al., “Production of hepatocyte-like cells from human amnion,” Methods in Molecular Biology, vol. 481, pp. 155–168, 2009. View at: Publisher Site | Google Scholar
  16. K. Anderson, R. Wilkinson, and M. H. Grant, “Assessment of liver function in primary cultures of hepatocytes using diethoxy (5, 6) chloromethylfluorescein and confocal laser scanning microscopy,” International Journal of Artificial Organs, vol. 21, no. 6, pp. 360–364, 1998. View at: Google Scholar
  17. W. Schormann, F. J. Hammersen, M. Brulport et al., “Tracking of human cells in mice,” Histochemistry and Cell Biology, vol. 130, no. 2, pp. 329–338, 2008. View at: Publisher Site | Google Scholar
  18. D. Piro, C. Piccoli, L. Guerra et al., “Hematopoietic stem/progenitor cells express functional mitochondrial energy-dependent cystic fibrosis transmembrane conductance regulator,” Stem Cells and Development. In press. View at: Google Scholar
  19. L. Guerra, T. Fanelli, M. Favia et al., “Na+/H+ exchanger regulatory factor isoform 1 overexpression modulates cystic fibrosis transmembrane conductance regulator (CFTR) expression and activity in human airway 16HBE14o- cells and rescues ΔF508 CFTR functional expression in cystic fibrosis cells,” Journal of Biological Chemistry, vol. 280, no. 49, pp. 40925–40933, 2005. View at: Publisher Site | Google Scholar
  20. M. F. Pittenger, A. M. Mackay, S. C. Beck et al., “Multilineage potential of adult human mesenchymal stem cells,” Science, vol. 284, no. 5411, pp. 143–147, 1999. View at: Publisher Site | Google Scholar
  21. K. Le Blanc, F. Frassoni, L. Ball et al., “Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study,” The Lancet, vol. 371, no. 9624, pp. 1579–1586, 2008. View at: Publisher Site | Google Scholar
  22. G. D'Ippolito, P. C. Schiller, C. Ricordi, B. A. Roos, and G. A. Howard, “Age-related osteogenic potential of mesenchymal stromal stem cells from human vertebral bone marrow,” Journal of Bone and Mineral Research, vol. 14, no. 7, pp. 1115–1122, 1999. View at: Publisher Site | Google Scholar
  23. R. J. Scheubel, H. Zorn, R. E. Silber et al., “Age-dependent depression in circulating endothefial progenitor cells in patients undergoing coronary artery bypass grafting,” Journal of the American College of Cardiology, vol. 42, no. 12, pp. 2073–2080, 2003. View at: Publisher Site | Google Scholar
  24. C. Heeschen, R. Lehmann, J. Honold et al., “Profoundly reduced neovascularization capacity of bone marrow mononuclear cells derived from patients with chronic ischemic heart disease,” Circulation, vol. 109, no. 13, pp. 1615–1622, 2004. View at: Publisher Site | Google Scholar
  25. P. S. In't Anker, S. A. Scherjon, C. Kleijburg-van der Keur et al., “Isolation of mesenchymal stem cells of fetal or maternal origin from human placenta,” Stem Cells, vol. 22, no. 7, pp. 1338–1345, 2004. View at: Publisher Site | Google Scholar
  26. F. Alviano, V. Fossati, C. Marchionni et al., “Term amniotic membrane is a high throughput source for multipotent mesenchymal stem cells with the ability to differentiate into endothelial cells in vitro,” BMC Developmental Biology, vol. 7, article 11, 2007. View at: Publisher Site | Google Scholar
  27. C. B. Portmann-Lanz, A. Schoeberlein, A. Huber et al., “Placental mesenchymal stem cells as potential autologous graft for pre- and perinatal neuroregeneration,” American Journal of Obstetrics and Gynecology, vol. 194, no. 3, pp. 664–673, 2006. View at: Publisher Site | Google Scholar
  28. N. Sakuragawa, K. Kakinuma, A. Kikuchi et al., “Human amnion mesenchyme cells express phenotypes of neuroglial progenitor cells,” Journal of Neuroscience Research, vol. 78, no. 2, pp. 208–214, 2004. View at: Publisher Site | Google Scholar
  29. S. Ilancheran, A. Michalska, G. Peh, E. M. Wallace, M. Pera, and U. Manuelpillai, “Stem cells derived from human fetal membranes display multilineage differentiation potential,” Biology of Reproduction, vol. 77, no. 3, pp. 577–588, 2007. View at: Publisher Site | Google Scholar
  30. P. Zhao, H. Ise, M. Hongo, M. Ota, I. Konishi, and T. Nikaido, “Human amniotic mesenchymal cells have some characteristics of cardiomyocytes,” Transplantation, vol. 79, no. 5, pp. 528–535, 2005. View at: Publisher Site | Google Scholar
  31. C. Ventura, S. Cantoni, F. Bianchi et al., “Hyaluronan mixed esters of butyric and retinoic acid drive cardiac and endothelial fate in term placenta human mesenchymal stem cells and enhance cardiac repair in infarcted rat hearts,” Journal of Biological Chemistry, vol. 282, no. 19, pp. 14243–14252, 2007. View at: Publisher Site | Google Scholar
  32. J. P. Wei, T. S. Zhang, S. Kawa et al., “Human amnion-isolated cells normalize blood glucose in streptozotocin-induced diabetic mice,” Cell Transplantation, vol. 12, no. 5, pp. 545–552, 2003. View at: Google Scholar
  33. R. M. Moore, R. J. Silver, and J. J. Moore, “Physiological apoptotic agents have different effects upon human amnion epithelial and mesenchymal cells,” Placenta, vol. 24, no. 2-3, pp. 173–180, 2003. View at: Publisher Site | Google Scholar
  34. M. L. Casey and P. C. MacDonald, “Interstitial collagen synthesis and processing in human amnion: a property of the mesenchymal cells,” Biology of Reproduction, vol. 55, no. 6, pp. 1253–1260, 1996. View at: Google Scholar
  35. S. Barlow, G. Brooke, K. Chatterjee et al., “Comparison of human placenta- and bone marrow-derived multipotent mesenchymal stem cells,” Stem Cells and Development, vol. 17, no. 6, pp. 1095–1107, 2008. View at: Publisher Site | Google Scholar
  36. S. Wolbank, A. Peterbauer, M. Fahrner et al., “Dose-dependent immunomodulatory effect of human stem cells from amniotic membrane: a comparison with human mesenchymal stem cells from adipose tissue,” Tissue Engineering, vol. 13, no. 6, pp. 1173–1183, 2007. View at: Publisher Site | Google Scholar
  37. T. Tamagawa, S. Oi, I. Ishiwata, H. Ishikawa, and Y. Nakamura, “Differentiation of mesenchymal cells derived from human amniotic membranes into hepatocyte-like cells in vitro,” Human Cell, vol. 20, no. 3, pp. 77–84, 2007. View at: Publisher Site | Google Scholar
  38. G. Bilic, S. M. Zeisberger, A. S. Mallik, R. Zimmermann, and A. H. Zisch, “Comparative characterization of cultured human term amnion epithelial and mesenchymal stromal cells for application in cell therapy,” Cell Transplantation, vol. 17, no. 8, pp. 955–968, 2008. View at: Google Scholar
  39. M. Bailo, M. Soncini, E. Vertua et al., “Engraftment potential of human amnion and chorion cells derived from term placenta,” Transplantation, vol. 78, no. 10, pp. 1439–1448, 2004. View at: Publisher Site | Google Scholar
  40. M. Soncini, E. Vertua, L. Gibelli et al., “Isolation and characterization of mesenchymal cells from human fetal membranes,” Journal of Tissue Engineering and Regenerative Medicine, vol. 1, no. 4, pp. 296–305, 2007. View at: Publisher Site | Google Scholar
  41. G. Pasquinelli, P. Tazzari, F. Ricci et al., “Ultrastructural characteristics of human mesenchymal stromal (stem) cells derived from bone marrow and term placenta,” Ultrastructural Pathology, vol. 31, no. 1, pp. 23–31, 2007. View at: Publisher Site | Google Scholar
  42. X. R. Tao, W. L. Li, S. Juan et al., “Clonal mesenchymal stem cells derived from human bone marrow can differentiate into hepatocyte-like cells in injured livers of scid mice,” Journal of Cellular Biochemistry, vol. 108, no. 3, pp. 693–704, 2009. View at: Publisher Site | Google Scholar
  43. K. Leelawat, S. Narong, S. Chaijan et al., “Proteomic profiles of mesenchymal stem cells induced by a liver differentiation protocol,” International Journal of Molecular Sciences, vol. 11, no. 12, pp. 4905–4915, 2010. View at: Publisher Site | Google Scholar
  44. S. Kazemnejad, A. Allameh, M. Soleimani et al., “Biochemical and molecular characterization of hepatocyte-like cells derived from human bone marrow mesenchymal stem cells on a novel three-dimensional biocompatible nanofibrous scaffold,” Journal of Gastroenterology and Hepatology, vol. 24, no. 2, pp. 278–287, 2009. View at: Publisher Site | Google Scholar
  45. J. K. Henderson, J. S. Draper, H. S. Baillie et al., “Preimplantation human embryos and embryonic stem cells show comparable expression of stage-specific embryonic antigens,” Stem Cells, vol. 20, no. 4, pp. 329–337, 2002. View at: Google Scholar
  46. E. J. Gang, D. Bosnakovski, C. A. Figueiredo, J. W. Visser, and R. C. Perlingeiro, “SSEA-4 identifies mesenchymal stem cells from bone marrow,” Blood, vol. 109, no. 4, pp. 1743–1751, 2007. View at: Publisher Site | Google Scholar
  47. E. Pierantozzi, B. Gava, I. Manini et al., “Pluripotency regulators in human mesenchymal stem cells: expression of NANOG but not of OCT-4 and SOX-2,” Stem Cells and Development, vol. 20, no. 5, pp. 915–923, 2011. View at: Publisher Site | Google Scholar
  48. D. J. Weiss, M. A. Berberich, Z. Borok et al., “Adult stem cells, lung biology, and lung disease. NHLBI/Cystic fibrosis foundation workshop,” Proceedings of the American Thoracic Society, vol. 3, no. 3, pp. 193–207, 2006. View at: Google Scholar
  49. G. Wang, B. A. Bunnell, R. G. Painter et al., “Adult stem cells from bone marrow stroma differentiate into airway epithelial cells: potential therapy for cystic fibrosis,” Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 1, pp. 186–191, 2005. View at: Publisher Site | Google Scholar
  50. A. Erices, P. Conget, and J. J. Minguell, “Mesenchymal progenitor cells in human umbilical cord blood,” British Journal of Haematology, vol. 109, no. 1, pp. 235–242, 2000. View at: Publisher Site | Google Scholar
  51. K. Mareschi, E. Biasin, W. Piacibello, M. Aglietta, E. Madon, and F. Fagioli, “Isolation of human mesenchymal stem cells: bone marrow versus umbilical cord blood,” Haematologica, vol. 86, no. 10, pp. 1099–1100, 2001. View at: Google Scholar
  52. S. A. Wexler, C. Donaldson, P. Denning-Kendall, C. Rice, B. Bradley, and J. M. Hows, “Adult bone marrow is a rich source of human mesenchymal “stem” cells but umbilical cord and mobilized adult blood are not,” British Journal of Haematology, vol. 121, no. 2, pp. 368–374, 2003. View at: Publisher Site | Google Scholar
  53. A. Ben-Chetrit, M. Antenos, A. Jurisicova et al., “Expression of cystic fibrosis transmembrane conductance regulator during early human embryo development,” Molecular Human Reproduction, vol. 8, no. 8, pp. 758–764, 2002. View at: Google Scholar
  54. X. T. Mo, S. C. Guo, H. Q. Xie et al., “Variations in the ratios of co-cultured mesenchymal stem cells and chondrocytes regulate the expression of cartilaginous and osseous phenotype in alginate constructs,” Bone, vol. 45, no. 1, pp. 42–51, 2009. View at: Publisher Site | Google Scholar
  55. L. Bian, D. Y. Zhai, R. L. Mauck, and J. A. Burdick, “Coculture of human mesenchymal stem cells and articular chondrocytes reduces hypertrophy and enhances functional properties of engineered cartilage,” Tissue Engineering A, vol. 17, no. 7-8, pp. 1137–1145, 2011. View at: Publisher Site | Google Scholar
  56. Y. Maeda, V. Dave, and J. A. Whitsett, “Transcriptional control of lung morphogenesis,” Physiological Reviews, vol. 87, no. 1, pp. 219–244, 2007. View at: Publisher Site | Google Scholar
  57. L. Badri, N. M. Walker, T. Ohtsuka et al., “Epithelial interactions and local engraftment of lung-resident mesenchymal stem cells,” American Journal of Respiratory Cell and Molecular Biology, vol. 45, no. 4, pp. 809–816, 2011. View at: Publisher Site | Google Scholar
  58. T. S. Jiang, L. Cai, W. Y. Ji et al., “Reconstruction of the corneal epithelium with induced marrow mesenchymal stem cells in rats,” Molecular Vision, vol. 16, pp. 1304–1316, 2010. View at: Google Scholar
  59. J. Xu, X. Liu, J. Chen et al., “Cell-cell interaction promotes rat marrow stromal cell differentiation into endothelial cell via activation of TACE/TNF-α signaling,” Cell Transplantation, vol. 19, no. 1, pp. 43–53, 2010. View at: Publisher Site | Google Scholar
  60. S. L. Farmen, P. H. Karp, P. Ng et al., “Gene transfer of CFTR to airway epithelia: low levels of expression are sufficient to correct Cl- transport and overexpression can generate basolateral CFTR,” American Journal of Physiology, vol. 289, no. 6, pp. L1123–L1130, 2005. View at: Publisher Site | Google Scholar
  61. C. Colombo, “Liver disease in cystic fibrosis,” Current Opinion in Pulmonary Medicine, vol. 13, no. 6, pp. 529–536, 2007. View at: Publisher Site | Google Scholar
  62. K. Moyer and W. Balistreri, “Hepatobiliary disease in patients with cystic fibrosis,” Current Opinion in Gastroenterology, vol. 25, no. 3, pp. 272–278, 2009. View at: Publisher Site | Google Scholar

Copyright © 2012 Valentina Paracchini et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

More related articles

2531 Views | 1231 Downloads | 31 Citations
 PDF  Download Citation  Citation
 Download other formatsMore
 Order printed copiesOrder

Related articles

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.